ClinicalTrials.gg
TerminatedNCT06706752Updated Nov 12, 2026

A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy

An interventional study of Shengbai Oral Formula and Inactive Placebo in Cancer, sponsored by Sutter Health. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Sutter Health · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Funding issues
Updated Nov 12, 2026Now TerminatedNow Suspended+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to assess whether Shengbai Oral Formula is a viable option for treatment of fatigue, pain, and neutropenia in patients undergoing their third cycle of chemotherapy.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 4 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Sutter Health is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-80 years of age
  2. A cancer diagnosis and scheduled to undergo at least three rounds of chemotherapy for curative or palliative intent
  3. Chemotherapy is given at a minimum of every 2 weeks
  4. At least 30 days past radiation therapy
  5. Nonpregnant and use of method of per the treating clinician standard of care
  6. > 3 months
  7. Stable on all herbal or complementary therapeutics for the past 30 days and agree to not include new complementary therapeutics until after study completion
  8. Baseline ≤ 2
  9. In the opinion of the investigator, the subject will be compliant and have a high probability of completing the study including all scheduled evaluations and required tests

Exclusion criteria

Exclusion Criteria:

  1. Abnormal /AST: > 2.5 to 3 times normal range
  2. \<60
  3. \< 75,000
  4. \<8.0
  5. ANC \<1000
  6. Documentation of a bone marrow transplant
  7. Documentation of , diagnosis with other cancer, except skin cancer history with basal cell carcinoma, squamous carcinoma
  8. Documentation of current seizure disorder
  9. Documentation of new cardiac arrhythmias and myocardial infarction
  10. Any active bacterial or viral infection, pneumonia, sepsis, active gastric ulcer, gastritis, nonhealing wound, intractable nausea or vomiting, diarrhea, bleeding disorder
  11. Hyperthyroidism, connective tissue disease including systemic lupus erythematous, rheumatoid arthritis
  12. Documentation of a current drug abuse disorder
  13. Current participation in other clinical trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Dietary Supplement: Shengbai Oral Formula

  • Placebo comparator
    Placebo Group

    Other: Inactive Placebo

Interventions

  • Dietary supplementShengbai Oral Formula

    Shengbai Oral Formula contains 11 herbs: Folium Epimedii, Fructus Lycii, Radix Astragali, Caulis Spatholobi, Radix Rubiae, Rhizoma Phragmitis, Fructus Psoraleae, Radix Angelicae Sinensis, Radix Ophiopogonis,, Radix et Rhizoma Glycyrrhizae, Radix Aconiti Lateralis Preparata (Processed). It is taken by mouth three times per day for 14 days.

  • OtherInactive Placebo

    Inactive placebo will be taken by mouth three times per day for 14 days.

06

What researchers measure

Primary outcomes

  1. Brief Fatigue Inventory

    The Brief Fatigue Inventory (BFI) is used to assess the severity and impact of fatigue, including cancer-related fatigue. Fatigue scores on the BFI are categorized as Mild (1-3), Moderate (4-6), and Severe (7-10).

    Time frame: 14 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2025 to primary completion in Sep 2025, 8 months.

Primary completion moved twice since we started tracking on Sep 25, 2026: Dec 2025 → Sep 2025, last on Nov 12, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Dec 2025 → Sep 2025, last on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 27, 2024
StartActual
Jan 24, 2025
Primary completionActual
Sep 29, 2025was Dec 2025
CompletionActual
Sep 29, 2025was Dec 2025
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended→Terminated Funding issues
changed Nov 6, 2026 · changed Nov 12, 2026
Primary completion
Dec 2025→Sep 29, 2025 (actual)
moved 2 times, Nov 6, 2026 – Nov 12, 2026
Study completion
Dec 2025→Sep 29, 2025 (actual)
moved 2 times, Nov 6, 2026 – Nov 12, 2026
Enrollment
30 (estimated)→4 (actual)
Nov 6, 2026
Show all 2 updates
  1. Nov 12, 2026
    Suspended→Terminated
    Primary completion Oct 1, 2027→Sep 29, 2025 (now actual)
    Study completion Dec 1, 2027→Sep 29, 2025 (now actual)
  2. Nov 6, 2026
    Recruiting→Suspended
    Why stopped Funding issues
    Primary completion Dec 2025→Oct 1, 2027
    Study completion Dec 2025→Dec 1, 2027
    Enrollment 30 (estimated)→4 (actual)
    + 5 other changes: verification date, oversight details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06706752
Lead sponsor
Sutter Health
Responsible party
Amy Matecki (Principal Investigator and Holistic/Integrative Medicine Physician, Sutter Health) — Principal investigator
First posted
Nov 27, 2024
Start date
Jan 24, 2025
Primary completion
Sep 29, 2025
Completion
Sep 29, 2025
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion